Home > Healthcare > Medical Devices > Diagnostic Devices > PARP Inhibitor Biomarkers Market

PARP Inhibitor Biomarkers Market Trends

Report ID: GMI9191
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

PARP Inhibitor Biomarkers Market Trends

Genomic technologies, including next-generation sequencing (NGS) and gene expression profiling, have transformed cancer research and treatment. These methods allow for the detection of precise genetic mutations and alterations that propel cancer advancement. For PARP inhibitors, genomic testing can pinpoint patients harbouring mutations in DNA repair pathways, like BRCA1 and BRCA2, enhancing the likelihood of response to PARP inhibitor therapy.

With increasing healthcare expenditure dedicated to cancer treatment, there is a growing emphasis on therapies that offer improved efficacy and fewer adverse effects.
PARP inhibitors represent a novel approach to cancer treatment, and investments in research and development have expanded the understanding of their mechanisms of action and potential biomarkers for patient stratification, propelling the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for PARP inhibitor biomarkers was USD 905.3 million in 2023 and is expected to register 8.3% CAGR from 2024-2032 owing to the increasing prevalence of cancer and growing demand for personalized mediations worldwide.

PARP inhibitor biomarkers industry from the kits segment is expected to record USD 1.1 million by 2032 due to increasing prevalence of cancer, particularly breast and ovarian cancers, heightening the demand for effective treatment options such as PARP inhibitors.

North America industry reached USD 369.4 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to growing occurrence of cancer in the region, particularly breast and ovarian cancers, which are key focuses for PARP inhibitors.

Agilent Technologies, Inc., Ambry Genetics, Amoy Diagnostics Co., Ltd., Centogene N.V, Illumina, Inc., Invitae Corporation, Myriad Genetics, Inc., Neogenomics, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., are some of the major PARP inhibitor biomarkers companies worldwide.